Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L
about
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleusPhosphoinositol lipids bind to phosphatidylinositol 3 (PI3)-kinase enhancer GTPase and mediate its stimulatory effect on PI3-kinase and Akt signalingsThe neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAPThe roles of PIKE in tumorigenesisGenetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomasMerlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survivalSchwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c)The tumor suppressor merlin is required for cell cycle exit, terminal differentiation, and cell polarity in the developing murine lensInvestigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cellsChildhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Neurofibromatosis type 2.p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides.Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary studyPhosphorylation of merlin regulates its stability and tumor suppressive activity.Targeting Pyk2 for therapeutic interventionThe tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis.Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1)A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathwaysPPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based ChemotherapyMerlin: a tumour suppressor with functions at the cell cortex and in the nucleus.Role of Merlin/NF2 inactivation in tumor biology.Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitorsPIKE GTPase are phosphoinositide-3-kinase enhancers, suppressing programmed cell death.Neuropathology for the neuroradiologist: Antoni A and Antoni B tissue patterns.Merlin, a multi-suppressor from cell membrane to the nucleus.Schwannomas and their pathogenesis.Molecular insights into NF2/Merlin tumor suppressor function.Regulation of Drosophila glial cell proliferation by Merlin-Hippo signaling.Schwannomas exhibit distinct size-dependent gene-expression patterns.Merlin sumoylation is required for its tumor suppressor activity.Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis related to or comparable with mechanisms seen in inflammatory pathways? Part II: angiogenesis- and inflammation-related molecular pathways, tumor-associated macroThe scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent mannerNovel age-dependent targets in vestibular schwannomas.
P2860
Q24300692-7E7BA4C0-012D-49C2-946E-DCD2D8552AD0Q24537693-25EA4732-707E-4F30-A315-3B5EB235B320Q24650089-8F6A3377-C473-470C-87EE-2A37E2789F5EQ27023876-F3EE41A9-B299-4078-8DAE-50DCB03B61B6Q28271306-8940D6D1-D0A2-4843-888B-AAFDC5E9DEFEQ28283076-78D22536-574C-4613-A428-C24211AA1A4DQ28298948-5B550457-42CF-441A-BAAD-F14A3362F1CAQ28590774-3CDB2986-DAB5-4285-8F5E-6615B49AFAC2Q28728224-DF4B0406-2303-4A6D-B092-DAF9F34F4726Q30364937-8FF5A45A-ECF6-47CE-848E-82E279EAA3AEQ30391375-1ECAE371-B649-4436-9B9E-FB5DCEFF2C66Q30401833-A695799F-0CAC-43F0-9B92-E7A72206EEBEQ30437229-447AD1EB-BB10-41E9-AC40-6D46067DC403Q30440530-E11B99AA-4C69-48D4-8756-9152F45E5CF8Q30459589-8465DA8F-610E-46D8-8E6D-5283B645E393Q30464280-6C09CEC2-8518-4387-AD02-3657D767AC3FQ30481231-883EFF27-48A1-4A80-918B-2A10DECB4013Q30487287-37A9570B-BE18-4A5B-A15F-1D2E98A51E45Q30488858-AF0483F1-8745-4742-ABDC-F6EDA7EAD943Q34146883-5890F5F5-2B99-4774-B26F-DEABD7B2BEA6Q34474913-A51B64F7-50C7-40CF-BA9C-BF0D31FE2532Q34620864-A6DA29CB-5258-4C3E-B398-D1C5389A5655Q35380714-093869B4-3554-4A5C-AD47-1C5EE46A2461Q35670477-5679CF05-9DD6-47CF-A647-460FB35331FDQ35737787-EB1FFB1E-7277-4657-938D-6FFA0F97AC02Q35880377-1C3D9B8A-FF8B-4005-8630-9243BAF865EDQ36189820-BE46672A-D8DA-4716-B9BC-66A0C1399E5AQ36346942-467C3D76-D840-41B5-BDAC-F730F90FFDFAQ36762621-A0D26B83-64F4-440A-88A2-1F2FE03D648DQ36950751-59BFFD32-0812-4C76-9590-2EF5F5920BE5Q38010858-66134601-5348-4E1D-8385-456198F206B5Q38180808-7AC70AEA-8C67-417A-AC62-E191062F1CA2Q38204110-469843DD-493C-44B4-8CFB-A9CFF5E744F8Q38979328-ECB67B33-FD7E-4A79-991A-DD28811DACFEQ38995513-46185A23-64A3-4C6B-AD12-0DDC5CCE16A5Q39069340-23C6F88D-685D-4643-9023-CD293EBF3306Q39173616-7E2A2D9E-239E-41E5-A54F-70061D67A878Q40343618-D0EC18F1-3123-4E5D-9AB5-5B4B694312AAQ41814702-D9CFAD56-AF47-48F1-9D2B-179213B278C0Q42122417-DE8B30B8-4087-4A0E-8491-5FC82D2C028E
P2860
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 December 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neurofibromatosis 2 (NF2) tumo ...... nase through binding to PIKE-L
@en
type
label
Neurofibromatosis 2 (NF2) tumo ...... nase through binding to PIKE-L
@en
prefLabel
Neurofibromatosis 2 (NF2) tumo ...... nase through binding to PIKE-L
@en
P2093
P2860
P356
P1476
Neurofibromatosis 2 (NF2) tumo ...... nase through binding to PIKE-L
@en
P2093
David H Gutmann
Keqiang Ye
Xiaoling Tang
P2860
P304
18200-18205
P356
10.1073/PNAS.0405971102
P407
P577
2004-12-14T00:00:00Z